HKMPDC
香港分子病理檢驗中心

FOR LAB USE ONLY

MOLECULAR DIAGNOSTIC REQUEST FORM

PATIENT INFORMATION

NAME: _____ (LAST NAME) _____ (FIRST NAME)

ID/PASSPORT NO: _____ DATE OF BIRTH: ____/____/____ (DD/MM/YY)

CLINICAL DIAGNOSIS: _____ GRNDER ☐ FEMALE ☐ MALE

SAMPLE INFORMATION

DATE OF COLLECTION: ____/____/____ (DD/MM/YY) TIME: ____/____ (HH/MM)

SAMPLE TYPE (Please select one) :

- ☐ Blood, Specify (EDTA, clotted)
- ☐ Paraffin Embedded Tissue (FFPE)
- ☐ EDTA Plasma
- ☐ Serum
- ☐ First Voided Urine
- ☐ Stool
- ☐ Nasopharyngeal Aspirate/Swab
- ☐ Autocyte/ThinPrep
- ☐ Body Fluid,Specify Type: _____
- ☐ Swab,Specify Type: _____
- ☐ Tissue,Specify Type: _____
- ☐ Other,Please Specify: _____

PATIENT CONSENT

☐ Confirmation of patient informed consent for genetic testing

REPORT INFORMATION

PHYSICIAN: _____

INSTITUTION: _____

PHONE: _____ FAX: _____

SIGNATURE: _____ DATE(DD/MM/YY): _____

Please put a "✓ " in the box(es) to indicate the test(s) to be performed.

Oncology Testing

- ☐ GAIA@MPD NGS Panel
- ☐ LUNG@MPD NGS Panel
- ☐ *ct*LUNG@MPD NGS Panel
- ☐ COLON@MPD NGS Panel
- ☐ *ct*BREAST@MPD NGS Panel
- ☐ ACTION@MPD NGS Panel
- ☐ Brain Cancer Panel (MGMT Promoter Methylation & Chromosome 1p/19q Deletion)
- ☐ BRCA1 & BRCA2 Gene Comprehensive Study
- ☐ Breast Immunohistochemistry Panel (ER, PR, HER2 & Ki-67)
- ☐ Endometrial Adenocarcinoma Classification Panel (POLE, MMR IHC & p53 IHC)
- ☐ IDH1 & IDH2 Gene Mutation Detection
- ☐ KIT & PDGFRA Gene Mutation Detection
- ☐ KRAS & NRAS Gene Mutation Detection
- ☐ Lung Cancer Panel I (EGFR, ALK FISH & ROS1 FISH)
- ☐ Lung Cancer Panel II (BRAF, MET ex.14 skipping & ERBB2 ex.20)
- ☐ Lung Cancer Panel III (EGFR, ALK IHC & ROS1 FISH)
- ☐ MAP2K1 (MEK1) & MAP2K2 (MEK2) Gene Mutation Detection
- ☐ Microsatellite Instability Test & MMR Immunohistochemistry
- ☐ AKT1 codon 17 Mutation Detection
- ☐ ALK Gene Rearrangement Detection by FISH
- ☐ BRAF codon V600 Mutation Detection
- ☐ CDKN2A/B Homozygous Deletion Detection by FISH
- ☐ Chromosome 1p/19q Deletion by FISH
- ☐ EGFR Gene Hotspot Mutation Detection (exon 18-21)
- ☐ EGFR Gene Amplification Detection by FISH
- ☐ ERBB2 exon 20 Mutation Detection
- ☐ ERBB2 (HER2) Gene Amplification by FISH | Fixation time ☐ <6 hrs ☐ 6-72 hrs ☐ >72 hrs
- ☐ ERBB2 (HER2) Immunohistochemistry
- ☐ ESR1 Gene Hotspot Mutation Detection (exon 5, 7 & 8)
- ☐ Histone 3 K27 / G34 Mutation Detection
- ☐ HRAS Gene Hotspot Mutation Detection (exon 2-4)
- ☐ HPV Detection and Genotyping (37 Genotypes) for FFPE
- ☐ KIT Gene Hotspot Mutation Detection (exon 9, 11, 13, 14 & 17)
- ☐ KRAS Gene Hotspot Mutation Detection (exon 2-4)
- ☐ MAPK1 E322K Mutation Detection
- ☐ MET exon 14 Skipping Mutation Detection
- ☐ MET Gene Amplification Detection by FISH
- ☐ MGMT Promoter Methylation by Methylation Specific PCR
- ☐ Microsatellite Instability Test
- ☐ MMR Immunohistochemistry
- ☐ NRAS Gene Hotspot Mutation Detection (exon 2-4)
- ☐ p53 Immunohistochemistry
- ☐ PALB2 Gene Comprehensive Study
- ☐ PDGFRA Gene Hotspot Mutation Detection (exon 12 & 18)
- ☐ PDL1 Immunohistochemistry ☐ 22C3 ☐ 28-8 ☐ SP263 ☐ SP142

Oncology Testing (Cont.)

- ☐ PIK3CA Gene Hotspot Mutation Detection (exon 10 & 21)
- ☐ PIK3CA Gene Hotspot Mutation Detection [Extended] (exon 2, 3, 5, 8, 10 & 21)
- ☐ POLE Gene Hotspot Mutation Detection (exon 9-14)
- ☐ RET Gene Rearrangement Detection by FISH
- ☐ RET Gene Hotspot Mutation Detection (exon 5, 8, 10, 11, 13-16)
- ☐ ROS1 Gene Rearrangement Detection by FISH
- ☐ TERT Gene Promoter Mutation Detection

Foundation Medicine / Oncotype

- ☐ FOUNDATIONONE CDx (324 cancer-related genes)
- ☐ FOUNDATIONONE LIQUID CDx (311 cancer-related genes)
- ☐ FOUNDATIONONE HEME Tissue (406 (DNA) & 265 (RNA) cancer-related genes)
- ☐ Oncotype DX Breast Recurrence Score test
- ☐ Oncotype DX Colon Recurrence Score test

Hereditary Cancer Screening

- ☐ APC Gene Comprehensive Study
- ☐ BRCA1 & BRCA2 Gene Comprehensive Study
- ☐ BMPR1A Gene Comprehensive Study
- ☐ CDH1 Gene Mutation Detection
- ☐ CHEK2 1100delC Mutation Detection
- ☐ EPCAM Gene Deletion Study
- ☐ MLH1 Gene Comprehensive Study
- ☐ MMR Genes Promoter Methylation Detection
- ☐ MSH2 Gene Comprehensive Study
- ☐ MSH6 Gene Comprehensive Study
- ☐ MUTYH Gene Comprehensive Study
- ☐ PMS2 Gene Comprehensive Study
- ☐ PTEN Gene Comprehensive Study
- ☐ RET Gene Hotspot Mutation Detection
- ☐ SLC25A13 Gene Mutation Detection
- ☐ STK11 Gene Comprehensive Study
- ☐ SMAD4 Gene Comprehensive Study
- ☐ TP53 Gene Comprehensive Study
- ☐ VHL Gene Comprehensive Study
- ☐ Specific Gene Known Mutation Screening (Point Mutation, Small Deletion and Insertion)
- ☐ Hereditary Cancer Panel (84 cancer-related genes)

Pharmacogenomics

- ☐ CYP2C9 & VKORC1 Genotyping for Warfarin Treatment
- ☐ CYP2C19 Genotyping for Clopidogrel Treatment
- ☐ DPYD Genotyping for 5-FU Responsiveness
- ☐ HLA-B*1301 Genotyping for Dapsone, Baktar or Phenytoin Treatment
- ☐ HLA-B*1502 Genotyping for Carbamazepine Treatment
- ☐ HLA-B27 Genotyping
- ☐ HLA-B*5801 Genotyping for Allopurinol Treatment
- ☐ NUDT15 Genotyping for Thiopurine Drugs Treatment
- ☐ TPMT Genotyping for Thiopurine Drugs Treatment
- ☐ UGT1A1 Genotyping for Irinotecan Toxicity

Others ☐ Please Specify: _____

MF 180/Ed 4.0/01 Jun 2024

Hong Kong Molecular Pathology Diagnostic Centre Limited
27/F, Strand 50, No. 50 Bonham Strand, Sheung Wan, Hong Kong
Tel: 2986 1213
Fax: 2527 7028